Skip to main
VYGR
VYGR logo

Voyager Therapeutics (VYGR) Stock Forecast & Price Target

Voyager Therapeutics (VYGR) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Voyager Therapeutics Inc is advancing its gene therapy portfolio with a focus on significant revenue growth tied to its TRACER platform, particularly from collaborations that are progressing into clinical trials expected in the 2030s. Preclinical results demonstrate considerable efficacy, with VY1706 achieving up to a 73% reduction in tau messenger RNA and over a 50% reduction in tau protein in non-human primates, indicating strong therapeutic potential with durable effects. Additionally, the company's innovative NeuroShuttle platform showcases enhanced central nervous system exposure and safety advantages, reinforcing Voyager's position in the gene therapy market for severe neurological diseases.

Bears say

The financial performance of Voyager Therapeutics indicates significant challenges, including a high burn rate and limited revenue generation, which raises concerns about the company's ability to sustain its operations and fund ongoing research and development. Moreover, the reliance on a narrow pipeline of gene therapies, particularly in a competitive and rapidly evolving field, presents risks related to clinical trial outcomes and market acceptance. Additionally, delays in trial progress and potential regulatory hurdles could further impact the company's ability to commercialize its therapies and achieve financial stability in the near term.

Voyager Therapeutics (VYGR) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Voyager Therapeutics (VYGR) Forecast

Analysts have given Voyager Therapeutics (VYGR) a Buy based on their latest research and market trends.

According to 5 analysts, Voyager Therapeutics (VYGR) has a Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Voyager Therapeutics (VYGR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.